ITM's subsidiary ITG and Nordic Nanovector have signed long-term global supply agreements for the medical radioisotope n.c.a. 177Lu / EndolucinBeta®

Read more

Förderung des FORActinium-Projekts durch die Bayerische Forschungsstiftung zur Entwicklung eines Herstellungsverfahrens für das in der zielgerichteten…

Read more

Key requirements met to start Ytterbium-176 irradiation at Bruce Power’s facilities for the production of ITM´s no-carrier-added Lutetium-177 for…

Read more

ITM announced today the appointment of Mona M Wahba, MD, MSM to the position of Deputy Chief Medical Officer.

Read more

Conclusion of an exclusive licensing and development agreement for Solucin® Targeted Radionuclide Therapy (TRT) in South Korea.

Read more

ITM announced today the appointment of Michael Lee-Chin to its supervisory board, starting May 23, 2019.

Read more

ITM announced today the lease of a new building in Neufahrn near Munich to increase the production capacity of no-carrier-added (n.c.a.) Lutetium-177…

Read more

ITM and UIH to collaborate in marketing and sales of ITM and UIH imaging and related products to clinical customers in China and worldwide.

Read more

ITM Isotopen Technologien München AG (ITM), a specialized group of radiopharmaceutical companies, announced today that it has received the Pharma…

Read more

The companies to combine their technologies to develop novel theranostic radiopharmaceuticals.

Merck to supply folate derivatives for the preparation…

Read more